Psutka, S. P., Imbroda, B. H., Crispen, P., Necchi, A., Garje, R., Szabados, B. E., Peyton, C., Pradere, B., Shore, N. D., Boegemann, M., Preston, M., Xylinas, E., Gong, C., Hasan, M., Stitou, H., Bhanvadia, S. K., Kim, W., Guerrero-Ramos, F. (2026). Neoadjuvant (Neoadj) gemcitabine intravesical system (Gem-iDRS) plus cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC) ineligible for/refusing neoadj cisplatin-based chemotherapy (NAC): Updated perioperative outcomes from SunRISe-4.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.748